Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 4/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.46 |
| ▸ | ITK | Q08881 | 3/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497792 | 0.85 | ULK1 (0.54) | ULK1BTKEGFRPTK2ITK | |
| SCHEMBL4565004 | 0.84 | ULK1 (0.58) | ULK1BTKEGFRPTK2ITK | |
| SCHEMBL4509298 | 0.84 | ULK1 (0.48) | ULK1BTKEGFRPTK2ITK | |
| SCHEMBL4493357 | 0.84 | LCK (0.48) | ULK1BTKEGFRPTK2ITK | |
| SCHEMBL4499343 | 0.82 | TBK1 (0.45) | ULK1BTKEGFRPTK2LCK | |
| SCHEMBL4496325 | 0.82 | JAK3 (0.57) | BTKEGFRPTK2LCKJAK3 | |
| SCHEMBL4491666 | 0.81 | BTK (0.65) | ULK1BTKEGFRPTK2ITK | |
| SCHEMBL4508785 | 0.81 | BTK (0.51) | BTKEGFRITKLCKJAK3 | |
| SCHEMBL4499608 | 0.80 | LCK (0.48) | ULK1BTKEGFRLCKJAK3 | |
| SCHEMBL4499562 | 0.80 | JAK3 (0.55) | BTKEGFRLCKJAK3TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | claimed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | ULK1 1992/4885BTK 1420/4885EGFR 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.